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Non–high-density lipoprotein cholesterol (non-HDL-C) as a terol (HDL-C) and increased plasma triglycerides due to
predictor of cardiovascular mortality in patients with end-stage accumulation of triglyceride-rich lipoproteins including
renal disease. very-low-density (VLDL) and intermediate-density lipo-Background. Patients with end-stage renal disease (ESRD)
proteins (IDL). Official recommendations in the generaloften show lipid abnormalities that may promote atherosclero-
population [2, 3] employ LDL-C in fasting blood as thesis. Although the standard lipid marker is low-density lipopro-
tein cholesterol (LDL-C) in official recommendations, the need gold standard lipid parameter in lipid-related risk assess-
of fasting blood sampling has prevented routine screening for ment. However, there are some problems in the use of
plasma lipids in hemodialysis patients. fasting LDL-C among ESRD patients treated by hemodial-Methods. We therefore evaluated the power of non–high-
ysis. First, the use of only LDL-C ignores the atherogenicdensity lipoprotein cholesterol (non–HDL-C) in predialysis
potentials of triglyceride-rich lipoproteins. The degree of(non-fasting) serum as a predictor of cardiovascular mortality
in a cohort of 525 hemodialysis patients. association of IDL and VLDL with aortic sclerosis was
Results. During the mean follow-up of 64 months, 120 deaths, greater than that of LDL in hemodialysis patients [4].
including 44 fatal cardiovascular events, occurred. Patients in Second, it is difficult for many patients to obtain bloodthe highest tertile of non–HDL-C (137 to 285 mg/dL) had a
samples after overnight fasting for standard lipid analy-significantly higher risk for cardiovascular mortality (HR, 3.065;
sis. Because plasma triglyceride level is greatly affected95% CI, 1.357% to 6.925%; P  0.007) in a univariate Cox
analysis. The association between non–HDL-C and cardiovas- by eating, the Friedewald formula gives falsely lower
cular mortality remained significant in multivariate Cox mod- LDL cholesterol if non-fasting specimens are used [5].
els, which included HDL-C, age, gender, duration of hemodial-
Recently, National Cholesterol Education Program Adultysis, blood pressure, presence of diabetes mellitus, serum
Treatment Panel III (NCEP ATP-III) [3] listed non–albumin, C-reactive protein, and body mass index.
Conclusion. Non–HDL-C in predialysis serum was a signifi- HDL-C [6], as well as LDL-C, as target lipid parameters
cant and independent predictor of cardiovascular mortality in in subjects with hypertriglyceridemia. Non–HDL-C is
hemodialysis patients. Non–HDL-C may be a useful marker the sum of LDL-C and cholesterol in triglyceride-rich
for risk assessment in routine practice, although predictive
lipoproteins, but can be easily calculated by subtractingpowers of this and the standard fasting LDL-C should be com-
HDL-C from total cholesterol. Because HDL-C is hardlypared in future studies.
affected by eating [5], non–HDL-C may be a better index
than LDL-C for routine practice in most of hemodialysis
patients. The purpose of this study was to evaluate thePatients with end-stage renal disease (ESRD) often
power of non–HDL-C taken at the start of the hemodial-have lipid and lipoprotein abnormalities that may ac-
ysis session in predicting cardiovascular outcome in acount for advanced atherosclerosis in this population [1].
cohort of hemodialysis patients.Total and low-density lipoprotein cholesterol (LDL-C)
levels are usually within normal range, whereas ESRD
patients show decreased high-density lipoprotein choles- METHODS
Study design and patients
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period of 1993 through 2000. In the present study, we
excluded 265 patients because of the lack of measure-
ments of non–HDL-cholesterol, and analyzed data from
525 out of the 790 patients in whom baseline non–HDL-C
was available. Mean ( SD) age was 55  11 years, and
the male:female ratio was 309:216. The underlying renal
diseases were chronic glomerulonephritis (N 311), dia-
betic nephropathy (N 96), polycystic disease (N 27),
nephrosclerosis (N 18), toxemia of pregnancy (N 10),
gout (N  9), lupus nephritis (N  7), chronic pyelone-
phritis (N  7), renal allograft failure (N  19), others
(N  13), and unknown (N  8). The follow-up was
performed until the end of 2000, and was 64 28 (mean
SD) months. This study was approved by the institutional Fig. 1. Kaplan-Meier curves of causes of death from cardiovascular
and non-cardiovascular death in relation to non–HDL cholesterol levelsethical committee (Inoue Hospital Approval No. 109).
in a cohort of 525 hemodialysis patients. The ranges of non–HDL
cholesterol in the lowest, middle, and highest tertiles were 1.09 to 2.74Serum lipids and other measurements
mmol/L (42 to 106 mg/dL), 2.76 to 3.51 mmol/L (107 to 136 mg/dL),
and 3.54 to 7.36 mmol/L (137 to 285 mg/dL), respectively. P valuesBlood samples were taken at the start of hemodialysis
were by log-rank test.session. Patients were not asked to stay fasted. Total
cholesterol was assayed by an enzymatic method, and
HDL-C by a precipitation method with dextran sulfate
and magnesium chloride. Other parameters were mea- 4.21 0.98 (163 38 mg/dL), 0.96 0.31 (37 12 mg/dL),
and 3.26  0.98 (126 38 mg/dL), respectively. The prev-sured by routine biochemical methods.
alence of total cholesterol 4.65 mmol/L (180 mg/dL),
Outcome data collection HDL-C 1.03 mmol/L (40 mg/dL), and non–HDL-C
3.36 mmol/L (130 mg/dL) was 28%, 63%, 41%, respec-Outcome data were obtained for all subjects by re-
viewing the hospital record forms. During the follow tively.
up, 120 deaths, including 44 fatal cardiovascular events
Univariate predictors of cardiovascular mortalityoccurred. The 44 cardiovascular deaths were attributable
to ischemic heart disease (N  12), cerebrovascular dis- In univariate Cox analysis, HDL-C was a negative
predictor (HR, 0.326 per 1 mmol/L; 95% CI, 0.108% toease (N  6), congestive heart failure (N  19), and
sudden death (N  7), as defined elsewhere [7]. The 0.985%; P 0.047), whereas non–HDL-C was a positive
predictor (HR, 1.553 per 1 mmol/L; 95% CI, 1.196% toother causes included infectious disease (N 26), cancer
(N  14), hepatic cirrhosis (N  5), cachexia (N  4), 2.016%; P  0.0009). The HR of those in the highest
tertile of non–HDL-C was 3.07 (95% CI, 1.36% to 6.23%,ileus (N  2), pulmonary embolism (N  1), acute pan-
creatitis (N  1), suicide (N  1), and unspecified (N  P  0.007) as compared with those in the lowest tertile
(Fig. 1). When the subjects were stratified into three22). These 76 cases were combined and analyzed as non-
cardiovascular deaths. groups using cut-off levels for non–HDL-C of 100 and
130 mg/dL, the HR of the group with the highest non–
Statistical analysis HDL-C was 3.62 (95% CI, 1.24% to 10.56%; P  0.018)
as compared with the group with the lowest non–HDL-C.Survival curves were estimated by the Kaplan-Meier
method, followed by log rank test. Prognostic variables Other significant univariate non-lipid predictors were
age (HR, 1.061 per year; 95% CI, 1.031% to 1.092%; Pwere evaluated by univariate and multivariate Cox pro-
portional hazards models, and summarized as hazards 0.0001), systolic blood pressure (HR, 1.025 per 1 mm Hg;
95% CI, 1.009% to 1.041%; P  0.002), and presenceratio (HR) and 95% confidence interval (CI). Signifi-
cance was defined as P  0.05. All of these calculations of diabetes mellitus (HR, 5.054 vs. non-diabetics; 95%
CI, 2.673% to 9.555%; P  0.0001). Gender, durationwere performed with statistical software (StatView 5,
SAS Institute Inc., Cary, NC, USA). of hemodialysis, serum albumin, C-reactive protein, and
BMI were not statistically prognostic for cardiovascular
mortality. Non–HDL-C did not predict non-cardiovascu-
RESULTS
lar mortality.
Total cholesterol, HDL-C, and non–HDL-C
levels at baseline Independent predictors of cardiovascular mortality
To evaluate whether the association of HDL-C andTotal cholesterol, HDL-C, and non–HDL-C showed
almost normal distributions, and mean SD levels were non-HDL-C with cardiovascular deaths are independent
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Table 1. Cox proportional hazards models showing the value of in hypertriglyceridemia. Third, previous cross-sectional
non-HDL cholesterol in predicting cardiovascular mortality in a
studies showed that non–HDL-C was an independentcohort of ESRD
factor associated with carotid artery intima-media thick-
Parameter Model 1 Model 2 ness [8] and aortic sclerosis [4, 7] in ESRD patients.
Non-HDL cholesterol 1.479 (1.109–1.973) 1.509 (1.104–2.063) And fourth, non–HDL-C predicts future cardiovascular
per 1 mmol/L P  0.008 P  0.009
mortality in a cohort of hemodialysis patients, as shownHDL cholesterol 0.531 (0.182–1.546) 0.565 (0.172–1.856)
per 1 mmol/L P  0.246 P  0.347 in the present study.
Age at entry 1.044 (1.014–1.075) 1.049 (1.015–1.084) It is convenient if overnight fasting is not required forper 1 year P  0.004 P  0.004
assessment of lipid-related risk. Because eating affectsDiabetes mellitus 3.314 (1.697–6.544) 4.005 (1.853–8.658)
presence vs. absence P  0.0006 P  0.0004 LDL-C, but not HDL-C, in non-uremic subjects [5], ca-
Systolic blood pressure 1.012 (0.997–1.028) 1.017 (1.001–1.034) sual sampling may be acceptable for non–HDL-C. Fur-per 1 mm Hg P  0.121 P  0.043
ther studies are needed to clarify postprandial changesGender — 1.049 (0.513–2.146)
female vs. male P  0.896 of individual lipid parameters in patients with ESRD.
Serum albumin — 0.987 (0.891–1.092) In the present study, we could not obtain sufficientper 1 g/L P  0.794
information on preexisting cardiovascular morbidity atC-reactive protein 1.003 (0.967–1.040)
per 1 g/L — P  0.884 baseline. Preexisting cardiovascular disease is one of the
Duration of hemodialysis — 1.005 (0.999–1.012)
important predictors of cardiovascular mortality [9].per 1 month P  0.106
Body mass index — 0.993 (0.875–1.127) Apolipoprotein B is also an independent factor associ-
per 1 unit P  0.912 ated with morbidity of myocardial infarction in hemodi-
Global model significance P  0.0001 P  0.0001
alysis patients [10]. Therefore, it is possible that the pre-
The table gives hazards ratios (95% confidence intervals) with statistical sig-
existing cardiovascular disease might have confoundednificance. Model 1 includes five covariates that are significant in univariate Cox
analysis. Model 2 includes five additional covariates that may be relevant. the association between non–HDL-C and cardiovascular
death during the follow up.
In conclusion, non–HDL-C in predialysis blood was
a significant and independent predictor of cardiovascularof other confounding variables, multivariate Cox models
mortality in hemodialysis patients. Therefore, use of ca-were used (Table 1). The first model, into which HDL-C,
sual non–HDL-C will provide a useful tool for risk as-non–HDL-C and the three significant non-lipid univari-
sessment among hemodialysis patients, although the pre-ate predictors were forced, showed that the positive asso-
dictive power of this and the standard fasting LDL-Cciation between non–HDL-C and cardiovascular mortal-
should be compared in future studies.ity remained significant, whereas the impact of HDL-C
was no longer significant. The close association between
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